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Abstract
To cause infections microbes need to evade host defense systems, one of these being the evolutionarily old and important
arm of innate immunity, the alternative pathway of complement. It can attack all kinds of targets and is tightly controlled in
plasma and on host cells by plasma complement regulator factor H (FH). FH binds simultaneously to host cell surface
structures such as heparin or glycosaminoglycans via domain 20 and to the main complement opsonin C3b via domain 19.
Many pathogenic microbes protect themselves from complement by recruiting host FH. We analyzed how and why
different microbes bind FH via domains 19–20 (FH19-20). We used a selection of FH19-20 point mutants to reveal the
binding sites of several microbial proteins and whole microbes (Haemophilus influenzae, Bordetella pertussis, Pseudomonas
aeruginosa, Streptococcus pneumonia, Candida albicans, Borrelia burgdorferi, and Borrelia hermsii). We show that all studied
microbes use the same binding region located on one side of domain 20. Binding of FH to the microbial proteins was
inhibited with heparin showing that the common microbial binding site overlaps with the heparin site needed for efficient
binding of FH to host cells. Surprisingly, the microbial proteins enhanced binding of FH19-20 to C3b and down-regulation of
complement activation. We show that this is caused by formation of a tripartite complex between the microbial protein, FH,
and C3b. In this study we reveal that seven microbes representing different phyla utilize a common binding site on the
domain 20 of FH for complement evasion. Binding via this site not only mimics the glycosaminoglycans of the host cells, but
also enhances function of FH on the microbial surfaces via the novel mechanism of tripartite complex formation. This is a
unique example of convergent evolution resulting in enhanced immune evasion of important pathogens via utilization of a
‘‘superevasion site.’’
Citation: Meri T, Amdahl H, Lehtinen MJ, Hyva¨rinen S, McDowell JV, et al. (2013) Microbes Bind Complement Inhibitor Factor H via a Common Site. PLoS
Pathog 9(4): e1003308. doi:10.1371/journal.ppat.1003308
Editor: Frank R. DeLeo, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States of America
Received October 7, 2012; Accepted March 2, 2013; Published April 18, 2013
Copyright:  2013 Meri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: TM is funded by the Academy of Finland, MJL by Maud Kuistila, Emil Aaltonen and Finnish Cultural Foundations, SM and TSJ by the Academy of
Finland, the Sigrid Juse´ius Foundation and the Helsinki University Hospital Funds (EVO), RM and JVM by NIH, NIDR (grant number: 5R01DE017401), and AG by the
Academy of Finland and the Sigrid Juse´lius Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: taru.meri@helsinki.fi
. These authors contributed equally to this work.
Introduction
Complement system (C) is an important part of innate
immunity in human plasma, and the alternative pathway of
complement (AP) is the first line of defense against invading
microbes. AP is spontaneously activated on all unprotected
surfaces leading to covalent binding of the main complement
opsonin C3b to hydroxyl or amine groups. Surface-attached C3b
forms a base for enzymatic convertases, which cleave intact C3-
molecules until the activator surface is covered with C3b-
molecules. This opsonization leads to opsonophagocytosis, prop-
agation of the cascade resulting in release of chemotactic and
anaphylatoxic peptides, and formation of lytic membrane attack
complexes. To prevent attack against host structures and over
consumption of the components in plasma, complement needs to
be tightly regulated.
The main regulator of the AP in plasma is factor H (FH). FH is
a 150 kDa glycoprotein and consists of twenty globular comple-
ment control protein modules (CCPs), each approximately 60
residues long. The AP control activity of FH is in domains 1–4
(FH1-4) [1,2]. The so-called cofactor activity of FH is needed for
inactivation of the central complement opsonin C3b by the serine-
protease factor I. In addition to this, FH regulates AP activation by
competing with factor B in binding to C3b and accelerating the
decay of AP convertase C3bBb [3,4]. To regulate complement,
FH has to discriminate between host and non-host surfaces, as
activation is warranted on microbial surfaces, but obviously not on
host surfaces. This ‘‘target recognition’’ site is known to be in the
carboxyl-terminal domains 19–20 (FH19-20) [5,6]. Our structures
of domains 19–20 alone [7] and complexed with C3d [8] showed
how SCR20 can bind to cellular and glycosaminoglycan
containing surfaces while SCR19 binds simultaneously to C3d
part of C3b facilitating control of the AP. This dual binding ability
facilitates target recognition by the AP.
The necessity of FH and its ability to distinguish between host
and non-host surfaces is demonstrated by mutations in the
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carboxyl-terminus of FH. Even heterozygous mutations in this
region can lead to uncontrolled AP activation on host cells causing
severe damage to endothelial cells, red cells, and platelets, resulting
in a serious systemic disease, atypical hemolytic uremic syndrome
[9]. Another important target binding region in FH is within
domain 7 and polymorphism in this domain is strongly associated
with age-related macular degeneration, the most common cause of
blindness in elderly people in industrialized countries [10,11].
FH is utilized by several pathogenic microbes for protection
against complement attack [12]. Binding of FH down regulates
opsonization and prevents further amplification of the C cascade
followed by formation of cytolytic membrane attack complexes.
While prevention of opsonization and subsequent phagocytosis is
beneficial for practically all microbes, evasion of membrane attack
complex formation is especially important for Gram-negative
bacteria and spirochetes. Acquisition of FH is important or even
essential for pathogens; increasing numbers of them have been
shown to bind FH [12]. There are two main interaction sites on
FH for microbial binding (Table S1); one is within domains 6–7,
and group A streptococci [13] and Neisseria [14], for example,
utilize this site. Binding via domains 6–7 facilitates also utilization
of FHL-1, an alternatively spliced transcript derived from FH-gene
which contains domains 1–7 of FH and has cofactor-activity like
FH [15]. Many microbes have been shown to bind both FH and
FHL-1 [16].
The other microbial interaction site on FH is in the carboxyl-
terminal domains 19–20. It seems that most microbes utilize both
sites: for instance, B. burgdorferi sensu stricto, which causes Lyme
disease, binds FH via domain 7 using protein CRASP-1 [17] and
via domains 19–20 using outer surface protein E (OspE) and its
paralogs [18]. This ability for dual binding facilitates efficient
protection against the AP attack. Due to the high homology
between the C-terminus of FH and C-termini of FH-related
proteins (FHRs), some microbes bind also certain FHRs but the
significance of this phenomenon for immune evasion is not clear
yet.
We wanted to analyze in detail how and especially why different
microbes utilize FH via the carboxyl-terminus. We selected
pathogens representing Gram-negative, Gram-positive, and eu-
karyote microbes known to bind FH, and three microbial proteins,
OspE (from B. burgdorferi sensu stricto) [18], FhbA (from B. hermsii)
[19], and Tuf (from P. aeruginosa) [20]. We discovered that they all
share a common binding site in domain 20 that overlaps but is not
identical with the heparin and cellular binding sites. We also
showed that FH bound to the microbial binding site forms a
tripartite complex with C3b and furthermore, formation of this
complex not only facilitates regulation of the AP but also enhances
it.
Results
A common microbial binding site on FH domain 20
We first characterized at the molecular level how microbes bind
FH via domains 19–20. We generated point mutations to 14
surface exposed residues of a recombinant fragment of FH
domains 19–20 and used five different microbes isolated from
patients: three Gram-negative bacteria P.aeruginosa (Pa) [20], (H.
influenzae (Hi) [21], B. pertussis (Bp) [22]), one Gram-positive
bacterium (S. pneumoniae (Sp) [23]), and one eukaryotic pathogen (C.
albicans (Ca) [24]). We also measured binding of full FH to strains
used and noticed they all bind FH, as expected on the basis of
previous reports (Figure S1).
Binding of 125I-labeled wild type (wt) FH19-20 was measured in
the presence of increasing amounts (up to 7 mM) of the mutant
FH19-20 constructs. Concentrations of the mutants that inhibited
50% of the wt FH19-20 binding (IC50) were calculated from
binding curves of three experiments done in triplicate (examples
are shown in Figure S2) and shown in Figure 1 as a reciprocal
value (1/IC50) for clarity (diminished value indicating diminished
binding). Three mutations, R1182A, R1203A, and R1206A,
caused decreased binding to all five microbes (p,0.05); K1188A
had reduced binding to four microbes (Hi, Pa, Sp, Ca); R1210A to
three (Hi, Pa, Sp); and the K1186A and R1215Q mutations
reduced binding to one microbe (Hi) (Figure 1). Four other
mutations (W1183L, T1184R, L1189R, E1198A) in domain 20
and three (D1119G, Q1139A, W1157L) in domain 19 showed no
reduction in binding compared to wt.
To further characterize interaction of FH with microbial
surfaces, similar binding inhibition assays were used with three
non-homologous and structurally unrelated bacterial outer surface
proteins: OspE, a 15 kDa protein from a Lyme borreliosis agent B.
burgdorferi [18], FhbA, a 20 kDa protein from a relapsing fever
spirochete B. hermsii [25], and Tuf, a 43 kDa protein from P.
aeruginosa [20]. Binding of 125I-FH19-20 to the recombinant
proteins was measured in the presence of increasing concentra-
tions of the 14 mutant proteins and the IC50 values were
calculated from the binding curves as above. When compared to
wt FH19-20, two mutant proteins, R1182A and R1206A, showed
decreased affinity to all the three microbial proteins, five mutants
(W1183L, L1189R, E1198A, R1203A, R1215Q) to two microbial
proteins and one mutant (R1210A) to one protein (p,0.05)
(Figure 2, Panels A–C, shown as a reciprocal value (1/IC50) for
clarity). The effect of three mutants (T1184R, K1186A, K1188A)
in domain 20 and three (D1119G, Q1139A, W1157L) in domain
19 was comparable to wt FH19-20 (p.0.05). Six of the mutants
showed decreased binding to both OspE and FhbA suggesting an
overlap of the binding sites. The overlap was confirmed using cross
inhibition assays with OspE and FhbA (Figure 2, Panels D and E).
Taken together, the binding inhibition assays revealed that all
mutants that affected binding were in the domain 20. Further-
Author Summary
Complement is an important arm of innate immunity.
Activation of this plasma protein cascade leads to
opsonization of targets for phagocytosis, direct lysis of
Gram-negative bacteria, and enhancement of the inflam-
matory and acquired immune responses. No specific signal
is needed for activation of the alternative pathway of
complement, leading to its activation on all unprotected
surfaces. Pathogenic microbes need to evade this path-
way, and several species are known to recruit host
complement inhibitor factor H (FH) to prevent the
activation. FH is important for protection of host cells,
too, as defects in FH lead to a severe autoreactive disease,
atypical hemolytic uremic syndrome. We have now
identified at the molecular level a common mechanism
by which seven different microbes, Haemophilus influen-
zae, Bordetella pertussis, Pseudomonas aeruginosa, Strepto-
coccus pneumoniae, Candida albicans, Borrelia burgdorferi
and B. hermsii, recruit FH. All microbes bind FH via a
common site on domain 20, which facilitates formation of
a tripartite complex between the microbial protein, the
main complement opsonin C3b, and FH. We show that, by
utilizing the common microbial binding site on FH20,
microbes can inhibit complement more efficiently. This
detailed knowledge on mechanism of complement eva-
sion can be used in developing novel antimicrobial
chemotherapy.
Microbial Acquisition of Factor H
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more, we identified one mutant (R1182A) with significantly
decreased binding to all the microbes or microbial proteins
analyzed and two mutants (R1203A, R1206A) with significantly
reduced binding to seven out of eight targets (p,0.05) (Table 1). In
addition, the three central residues in microbial binding, R1182A,
R1203A, and R1206A, are close to each other in the crystal
structure of FH19-20 [7]. They are within 14 A˚ of each other on
domain 20 and three residues (K1188A, R1210A, R1215Q)
Figure 1. Microbial binding site on FH19-20. Pseudomonas aeruginosa (A), Haemophilus influenzae (B), Bordetella pertussis (C), Streptococcus
pneumoniae (D), and Candida albicans (E) were coated to microtitre plates and binding of 125I-FH19-20 was measured in the presence of serial
dilutions of 14 mutant proteins. Bound radioactivity was measured and the IC50 values (the 50% inhibitory concentration in mM) were determined by
fitting these measurements to inhibition curves (Figure S2). Means of the reciprocal values of IC50 (1/IC50) with SDs of three individual experiments
performed in triplicate are shown with difference compared to the wildtype (wt) calculated by a t-test. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.ppat.1003308.g001
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involved in binding to several microbes are also nearby (Figure 3).
Folding of all these mutants was comparable to wt FH19-20
according to a circular dichroism analyses (Figure S3).
Microbes mimic host surfaces upon binding to FH20
One binding site for glycosaminoglycans/heparin is located at
FH domain 20 [26]. We next analyzed if microbes could utilize
Figure 2. Binding site for microbial proteins on FH19-20. Three recombinant FH19-20 binding microbial proteins, OspE (A, D), FhbA (B, E) and
Tuf (C) were coated to microtitre plates. First, inhibition of binding of 125I-FH19-20 by the FH19-20 mutants (A–C) was measured, data fitted to
inhibition curves and IC50 values (the 50% inhibitory concentration) determined. Data shown are means of 1/IC50 values from three experiments
performed in triplicate (bars indicating SDs); differences compared to wt were calculated by a t-test (*p,0.05, **p,0.01, ***p,0.001). Second,
inhibition of binding of 125I-FH19-20 to OspE (D) or FhbA (E) by microbial proteins, OspE, FhbA, and a negative control OspA, was measured. Data
from representative experiments performed in triplicate are shown with SDs (D, E).
doi:10.1371/journal.ppat.1003308.g002
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this site by analyzing binding of 125I-FH19-20 to OspE, FhbA, and
Tuf in the presence of heparin, a model substance for cell surface
glycosaminoglycans. We showed that heparin inhibits binding of
FH19-20 efficiently to Tuf and slightly also to OspE and FhbA
(Figure 4). The data are consistent with previous data showing that
glycosaminoglycans bind to residues R1203, R1206, R1210, and
R1215 at the very carboxyl-terminus of FH20 [27]. This suggests
that the microbial binding site on FH overlaps to some extent with,
but is not identical to, the heparin binding site needed for
recruitment of FH to eliminate C3b on host cells.
Down-regulation of the AP by FH on host cells occurs because
FH20 binds to glycosaminoglycans/heparin while FH19 binds
simultaneously to the C3d part of C3b [8,28]. Next we tested if
microbes could utilize FH similarly, i.e. facilitating a two point
binding of FH19-20 to surface-bound C3b, one site binding to
the microbial protein and the other to C3b. There are two
binding sites on FH19-20 for the central complement opsonin
C3b, one in domain 19 and the other in domain 20 [8].
Structural analysis shows that the site on domain 20 overlaps
with the microbial site, while the site on domain 19 of FH is
clearly distinct from it [8]. In agreement with our model,
binding of C3d did not inhibit binding of FH19-20 to the
microbial proteins (Figure 4, panels A–C) but, to our surprise,
actually enhanced it.
Formation of a tripartite complex between microbial
protein, FH19-20, and C3b
As C3d enhanced binding of FH19-20 to microbial proteins, we
analyzed further if microbial proteins could enhance binding of
FH19 to its main physiological ligand, C3b. We measured the
binding of 125I-FH19-20 to C3b in the presence of OspE, FhbA,
and Tuf. OspE and FhbA enhanced binding of FH19-20 to C3b
statistically significantly while enhancement with Tuf was smaller
and not significant (Figure 5, Panel A). This suggests that a
microbial protein, FH19-20, and C3b together form a tripartite
complex. We were able to prove this by measuring binding of 125I-
OspE to solid phase C3b in the presence of FH19-20 (Figure 5,
Panel B). This means that the tripartite complex must form,
because OspE alone does not bind C3b [18]. Mutation of four
central residues in the C3d/C3b binding site on domain 19 of FH
(FH19del-20) [8] significantly reduced the formation of the
tripartite complex, indicating that the C3d/C3b binding site on
domain 19 is essential for the interaction (Figure 5, Panel B). These
experiments show that FH19-20 can bind simultaneously to a
microbial protein and C3b, and that binding of microbial proteins
to FH19-20 enhances the FH-C3b interaction. To further test
formation of the tripartite complexes on microbial surfaces we
measured effect of C3d (100 mg/ml) on binding of FH19-20 to the
surface of whole microbes (B. burgdorferi, S. pneumoniae, P. aeruginosa,
H. influenzae and C. albicans). A small increase in FH19-20 binding
was observed with all the used microbes, most clearly with S.
pneumoniae and C. albicans (Figure S4). No binding of 125I-C3d to
any microbes was seen (data not shown).
By modeling the tripartite complex on a surface using the
structure of FH19-20 in complex with C3d [8], C3b (containing
the C3d part) [29], and our recent crystal structure of FH19-20 in
complex with borrelial OspE protein (Bhattacharjee et al.,
submitted), a model of a microbial surface protein, we could also
show that formation of a tripartite complex is possible without any
steric clashes. Furthermore, in this model the thioester site of C3b
faces towards the membrane indicating that a surface-bound
microbial protein can enhance binding of FH to C3b on the same
surface (Figure 5, Panel C).
Binding to a microbial protein enhances the regulatory
function of FH
The results above suggested that, by enhancing the interaction
between FH and C3b, microbes might be able to down-regulate
complement activation more efficiently. The main regulatory
function of FH is to act as a cofactor for serine protease factor I in
inactivation of C3b. We therefore measured the cofactor activity of
full length FH in factor I mediated cleavage of C3b in the presence
of the three microbial proteins, OspE, FhbA, or Tuf (Figure 6,
Panels A and B). All tested microbial proteins enhanced
Table 1. Summary of the FH19-20 binding results.
FH19-20 mutation Pa Hi Bp Sp Ca OspE FhbA Tuf
D1119G 0.3* 0.4 0.3 0.4 0.7 0.6 0.9 0.5
Q1139A 0.8 1.0 1.1 0.9 1.4 1.2 1.1 0.2
W1157L 0.7 1.0 0.6 1.1 1.2 1.4 1.4 0.7
R1182A 4.0 4.9 1.9 3.3 3.9 3.0 18.0 5.0
W1183L 1.1 1.2 0.7 1.5 2.0 97.1 66.4 1.2
T1184R 0.3 0.4 0.2 0.6 0.5 1.2 1.7 0.6
K1186A 1.6 2.3 0.7 1.2 1.4 0.2 0.5 0.2
K1188A 3.5 4.0 1.7 4.1 4.1 0.8 1.6 1.3
L1189R 0.6 0.8 0.4 1.0 0.8 2.9 4.9 1.3
E1198A 0.3 0.4 0.3 0.6 0.4 24.7 25.1 0.2
R1203A 6.2 8.6 3.2 5.0 3.5 4.7 41.9 1.5
R1206A 2.2 4.8 2.0 2.9 3.7 3.4 3.1 3.1
R1210A 2.1 3.0 1.5 2.0 1.6 1.3 1.8 2.3
R1215Q 1.7 2.5 1.4 1.7 1.8 33.8 2.0 1.6
*The values represent relative binding of FH19-20 mutants vs. wild type FH19-20 (IC50mut/IC50wt) to microbes (Pa; Pseudomonas aeruginosa, Hi; Haemophilus
influenzae, Bp; Bordetella pertussis, Sp; Streptococcus pneumoniae, Ca; Candida albicans) or microbial proteins (OspE, FhbA, Tuf). Bold font of the value indicates
statistically significant increase in IC50 (i.e. diminished binding) when compared to wild type FH19-20 (unpaired t-test, p,0.05).
doi:10.1371/journal.ppat.1003308.t001
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significantly the cofactor activity of FH (p,0.05 at $20 mg/ml for
all of the proteins). The enhancement was due to the carboxyl-
terminal part of FH, since it did not clearly occur when FH1-4 was
used instead of full length FH (Figure 6, Panel C), i.e. enhancement
obviously requires domains 19 and 20 that mediate formation of
the tripartite complex.
Discussion
Escape of the complement system, and especially its alternative
pathway amplification cascade, is a prerequisite for microbial
virulence since this first line immune mechanism is spontaneously
activated on all non-protected surfaces. Microbes are known to
protect themselves by binding host complement regulators from
plasma or other body fluids: FH for protection against the
alternative pathway activation and C4b-binding protein for
inhibition of the classical and lectin pathways. Binding of FH
has been thought to be simple recruitment of host FH onto the
microbial surface since FH acts as a cofactor for factor I in the
degradation of the central complement component C3b [30]. This
inactivation is essential for microbial survival in nonimmune
plasma or blood, since it prevents opsonophagocytosis and
microbial lysis by the membrane attack complexes [31]. Microbes
recruit host FH by binding it via two separate sites, one within the
Figure 3. Microbial binding site on the structure of FH20. Panel A shows location of the binding sites of Pseudomonas aeruginosa,
Haemophilus influenza, Bordetella pertussis, Streptococcus pneumoniae, Candida albicans, OspE, FhbA, and Tuf on the surface of the crystal structure of
FH19-20 [7]. The involved residues are shown in red and in each figure the FH domain 19 is on the top and domain 20 on the bottom. In the panel B
the common microbial binding site is marked on the surface model of FH19-20. Residues affecting binding of FH19-20 to three or more microbes
(Table 1) are marked in red, other analyzed mutated residues are marked in blue and all residues have been annotated.
doi:10.1371/journal.ppat.1003308.g003
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domains 6–7 and the other in the C-terminal FH19-20 (Table S1),
but the reason for using these sites has remained unexplained.
Our new data show, first, that the microbes we studied not only
use FH19-20, but in particular the same area on FH domain 20,
which we have named the ‘‘common microbial binding site’’
(Figure 3, panel B). Second, our data show that binding via this
particular site allows the formation of a tripartite microbial
protein:FH:C3b complex (Figure 5, panel C). Third, and most
importantly, our data show that formation of the tripartite
complex enhances FH-mediated inactivation of C3b. This
explains why many kinds of microbes have evolved to utilize this
common microbial binding site on FH.
We analyzed the interaction site between the carboxyl-terminus
of FH and microbes by measuring the effect of mutant FH19-20
proteins on binding of wt FH19-20 to five important human
pathogens (Gram-negative and Gram-positive bacteria and a
yeast). Next we analyzed FH19-20 binding by three structurally
non-related, FH binding proteins, two from spirochetes, OspE
from B. burgdorferi sensu stricto [18] and FhbA from B. hermsii [32],
and Tuf from P. aeruginosa [21]. To our great surprise all the
microbes and microbial proteins studied bound FH via heavily
overlapping binding sites on domain 20 (Table 1, Figure 3, panel
A). We found three key amino acids (R1182, R1203, R1206) that
affected binding to all the studied microbes and three more
(K1188A, R1210A, R1215A) that affected binding to at least three
out of seven microbes analyzed. We believe that this site, the
common microbial binding site, will be found to be used by many
other pathogenic microbes too. We did not use full length FH with
point mutations in these experiments since microbes have often
two binding sites for FH (Table 1) and expression and purification
of full-length FH with mutations in both the microbial binding
sites might not result in easily interpretable results.
Since the different microbial proteins are non-homologous it is
expected that they use slightly different residues within or next to
the common microbial binding site on FH20 to form, for example,
hydrogen bonds and hydrophobic contacts. An example of this is
seen with OspE since mutations of two residues of FH19-20
(W1183 and E1198) that are not used by several other microbes
had the most striking effect on OspE binding to FH19-20. Use of
variable residues within the same area does not compromise the
key finding that the used microbes share a common binding area
on FH domain 20 but indicates variability in the structure of the
microbial molecules binding to the common shared site on FH. It
is obvious that only detailed structural analysis of different
microbial FH-binding proteins in complex with FH19-20 will
show how important each residue within or next to the common
site is for the interaction.
At least three non-homologous microbial proteins and, in
addition, four microbial species without known homologues of
these proteins utilize the same site on FH20. For some of these
microbes, it is not known which surface molecule recruits host FH
and it is possible that, at least in some cases, the surface molecules
are not proteins but carbohydrates. FH is known to bind to several
negatively charged carbohydrates [33] and the common microbial
binding site on FH20 overlaps with the site responsible for binding
to at least one host carbohydrate, heparin (Figure 4, panels A–C)
[27]. It remains to be studied if any microbe binds to the common
microbial binding site on FH20 via a carbohydrate, and if
carbohydrate binding to FH domain 20 could promote the
FH:C3b interaction through formation of a tripartite complex,
similarly to the studied microbial proteins.
Why have different microbes evolved to utilize domain 20, and
practically the same particular site on this domain, in recruitment
of FH? Our results provide three reasons for this. First, our work
shows that FH bound to microbial surface via domain 20 can also
bind the C3d part of C3b by domain 19 (Figure 5, panels A and
B). This brings FH near to its main target, C3b, and allows
complement inhibition. On the basis of the superimposition of
three structures, our recently solved structure of a microbial FH-
binding protein (OspE) in complex with FH19-20 (Bhattacharjee
et al, submitted) and the previously solved structures of FH19-20
in complex with C3d, [8] and of the C3b (containing the C3d
[29]), it became clear that FH19-20 can bind simultaneously to a
microbial protein and C3b (Figure 5, panel C). Furthermore, in
Figure 4. The common microbial binding site on FH20 overlaps
partially with the heparin but not the C3d binding site. Effect of
increasing concentrations of C3d, heparin, and FH19-20 in binding of
125I-FH19-20 to solid phase OspE (panel A), FhbA (panel B), or Tuf
(panel C) is shown (counts per minute (cpm) 6 SD from a
representative of three experiments performed in triplicates is shown).
doi:10.1371/journal.ppat.1003308.g004
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this superimposition the microbial binding site is also directed
towards the surface to which C3b is bound to via the thioester site
and is therefore readily available for the microbial molecules in
general. Second, the site on domain 20 is available under
physiological conditions: the previously described physiologically
important heparin binding site [27,34,35] and the common
microbial site overlap to some extent (Figure 4, panels A–C).
Ferreira and coworkers [36] have also emphasized that the
cofactor site on domains 1–4 must not be disturbed upon binding
of FH to a microbe and our common microbial binding site fulfills
also this criterion. Third, utilization of this particular common
microbial binding site provides more efficient down regulation of
Figure 5. Binding of FH20 to microbial proteins enhance the FH-C3b interaction. Panel A shows enhanced binding of radiolabeled FH19-
20 to solid phase C3b in the presence of 1.25 mM OspE, FhbA, or Tuf compared to buffer control (cpm 6SD from a representative experiment
performed in triplicates is shown; difference to the control was calculated by a t-test; *p,0.05, **p,0.01, ***p,0.001). In panel B, binding of 125I-
OspE to C3b (or bovine serum albumin, BSA, as a negative control) is shown in the presence or absence 1.25 mM of FH19-20 or FH19Del-20 lacking the
C3d binding site on FH domain 19 (cpm 6SD from a representative experiment performed in triplicates is shown). Panel C shows solvent accessible
surface representation of a model of the tripartite complex between FH19-20, C3b, and a microbial protein on a microbial surface. Two projections
with the microbial membrane lipid bilayer on the bottom are shown. Color code: C3b (2WII, [44]) is shown in blue and its C3d part (TED domain) is
darker blue with the thioester site in orange (1C3d, [7]); a microbial protein is shown in yellow; FH19-20 is shown in grey (2g7i, [8]).
doi:10.1371/journal.ppat.1003308.g005
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complement activation on the microbe. The intact a9-chain of
C3b disappears more efficiently when FH and microbial proteins
are present (Figure 6, Panels A and B). This is due to the carboxyl-
terminus of FH, as practically no enhancement was seen by using
FH1-4, which has cofactor activity but does not have the common
microbial binding site on domain 20 (Figure 6, Panel C).
The tripartite microbial protein:FH:C3b/C3d complexes are
clearly formed in fluid phase in vitro (Figure 5). It is, however,
uneasy to demonstrate the complex formation on microbial
surface since C3b is bound covalently to the molecules on the
target surface and the formed tripartite complex is easily broken
upon purification of C3b from the cells. To indicate the complex
formation on cell surfaces we therefore used an experimental setup
where binding of FH19-20 to whole intact microbes was analyzed
in the presence of soluble C3d and saw that addition of C3d could,
indeed, enhance the binding (Figure S4). Since the extrinsic C3d
can enhance binding of FH onto the microbial surface it is highly
likely that the microbial proteins could also enhance formation of
the tripartite complex on the microbial surface, at least if the
density of C3b depositions was high enough. The highest C3b
concentration occurs on the target surface areas where alternative
pathway activation is vigorously amplified via the feedback loop. It
would be most beneficial for the microbe if the tripartite
complexes were formed within those areas leading to maximal
complement down regulation exactly at the spots where it is
needed most. For the tripartite complex formation the microbial
FH-binding molecule needs to be – or bend – next to the C3b
molecule but most, if not all, of the FH-binding microbial proteins
which have been structurally characterize are either long
molecules (e.g. streptococcal M protein) or have a flexible tail
that allows twisting and tilting (e.g. OspE, Bhattacharjee et al,
submitted). Therefore at least some of the microbial FH-binding
molecules seem to be able to operate on a broader area of the
surface than just the exact spot they are attached to. The area
where the tripartite complexes could be formed might in addition
be expanded by lateral movement of the lipid tail or membrane
anchor of the microbial FH-binding molecules on at least surface
of Gram-negative bacilli.
An FH-related protein found in plasma, FHR-1, has a C-
terminal domain that differs from domain 20 of FH only by two
residues. The differences are located close to the microbial binding
site and it remains to be studied if FHR-1 binds similarly to the
used microbes, and if possible recruitment of FHR-1 is function-
ally beneficial or unfavourable for the microbes as FHR-1 does not
have any cofactor-activity.
Clearly, formation of the tripartite complex is the reason for the
increase in the regulatory function of FH caused by the microbial
proteins. As far as we know, this kind of enhancement has neither
been suggested, nor studied before. Instead, it has been suggested
that microbes mimic host structures and thereby bind FH and
other complement regulators [37]. Although microbes, heparin or
endothelial cells do bind to overlapping sites on FH, this is not
exactly molecular mimicry as the binding sites are not identical.
The structures involved are completely different and they appear
to differ from organism to organism. We and others have recently
shown that host cells recruit FH via domain 20 [27,35] and it
remains to be studied if this leads to elevated FH function due to
tripartite complex as in the microbial proteins [8,28]. If this were
the case, microbes utilizing the common microbial binding site on
FH domain 20 would have functional, not molecular, mimicry of
host cells. So far there is, however, no evidence of this.
The identified common microbial binding site on FH domain
20 represents a surprising type of host-pathogen contact – a single
site on a host molecule utilized by several kinds of microbes in
immune evasion. Such a common immune evasion site for both
bacterial and eukaryotic pathogens has not been reported earlier.
We call this kind of conserved site for microbial immune evasion a
‘‘superevasion site’’ and suggest that superevasion sites may occur
on other powerful down regulators of host immunity, too. The
concept of a microbial superevasion site is valid not only for down
regulators of immunity, such as FH, but also for host immune
activator molecules such as immunoglobulins. It is probable that,
for example, staphylococcal protein A [38], streptococcal protein
G [39], and E. coli protein EibD [40] are not the only microbial
proteins that bind to a conserved site on IgG leading to prevention
of the effector functions of immunoglobulins. This site on the Fc
part of IgG is probably an example of a superevasion site on
immune activator molecules.
In this study we have identified a conserved microbial binding
site on domain 20 of the important complement regulator FH. We
have shown that, by binding to the common binding site on FH,
microbial proteins enhance the FH:C3b interaction by enhancing
their interaction, thereby increasing down regulation of C3b and
leading to efficient evasion of complement attack and presumably
to increased survival of the microbes in the host. The identified
common microbial binding site on FH is the first example of a
Figure 6. Enhanced cofactor-activity of FH bound to microbial
proteins. Effect of OspE, FhbA, and Tuf (each 50 mg/ml) in elimination
of C3b by FH (8–85 mg/ml) and factor I (15 mg/ml). Cleavage of the a9-
chain of 125I-C3b was measured by evaluating the intensity of the a9-
chain in autoradiography (example gel from one out of three
experiments shown in panel A with mobility of the C3b fragments
and size markers indicated) and intensity in the absence of FH was set
as 100% (panel B). As a control, FH was replaced with recombinant FH1-
4 fragment (C). Data in panels B and C are from three independent
experiments with SDs indicated. * p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.ppat.1003308.g006
Microbial Acquisition of Factor H
PLOS Pathogens | www.plospathogens.org 9 April 2013 | Volume 9 | Issue 4 | e1003308
‘‘superevasion site’’ pointing to new avenues not only in research
on immune evasion by microbes but also in research aimed at
novel vaccines and antimicrobial agents.
Materials and Methods
Proteins
The outer surface proteins OspE and OspA from B. burgdorferi
sensu stricto strain N40 were cloned, expressed and purified as
described [18]. FhbA was cloned and purified from B. hermsii strain
MAN [32], and Tuf from a P. aeruginosa blood isolate strain
similarly as described earlier [20]. Cloning and purification of wt
FH19-20 and the FH19-20 mutants have been described earlier
[7,27,41]. Circular dichroism spectras of six mutants (R1182A,
W1183L, K1188A, E1198A, R1203A, R1206A) were compared
to wt to confirm proper folding of the mutants (Figure S3, panel
A). The capacity of these mutants to form oligomers was compared
to wt FH19-20 using gel filtration on a Superdex 75 10/300 GL
column (Figure S3, panel B). FH1-4 was produced as described
[42]. C3 and FH were purified from human plasma and C3b
generated with trypsin as described [43]. C3d was a kind gift from
Prof. D. Isenman, Univ. of Toronto, Canada. Factor I was
purchased from Calbiochem/MerckMillipore (Merck, Darmstadt,
Germany) and BSA, gelatin and heparin from Sigma-Aldrich (St.
Louis, MO, US). The wt FH19-20, FH, OspE, and C3b were
labeled with 125I using the IodoGen method (Thermo Scientific
Pierce, Rockford, IL, US).
Bacteria
The strains of Pseudomonas aeruginosa, Haemophilus influenzae,
Streptococcus pneumoniae, Staphylococcus aureus and Candida albicans we
used were isolated from blood cultures of septic patients and were
kind gifts of Dr. K. Haapasalo-Tuomainen, HUSLAB, Helsinki
Univ. Central Hospital, and Univ. of Helsinki, Finland. Bordetella
pertussis was a kind gift of Dr. Quishui He, Pertussis Reference
Laboratory, Turku, Finland. The used serum sensitive Haemophilus
influenzae strain is isolated from a throat swab of a healthy
individual.
Direct binding assays
To detect binding of FH or FH19-20 to the microbes, the
bacteria and yeast were first washed three times with PBS.
Approximately 16108 cells/reaction were incubated with radio-
labeled FH or FH19-20 (40,000 cpm/reaction) in the absence or
presence of C3d (0–100 mg/ml) in 50% PBS containing 0.1%
gelatin (GPBS) at 37uC for 20 min with agitation (1,200 rpm).
Cell-associated and free radioactive proteins were separated by
centrifugation (10,0006 g, 3 min) of the samples through 20%
sucrose in GPBS. Radioactivities in the supernatant and pellet
fractions were measured with a gammacounter (Wallac, Turku,
Finland). The amounts of bound proteins were calculated as
percentages of the total radioactivities in the corresponding pellets
and supernatants. The experiments were performed three times in
triplicate.
Radioligand assays and data processing
Nunc Polysorp BreakApart plates (Thermo Scientific, Rockford,
IL, US) were coated with either bacteria (16106/well in
phosphate-buffered saline, PBS, at 37uC for 12 hours) or proteins
(5–25 mg/ml in PBS at 4uC for 12 hours). The wells were blocked
(0.5% BSA/PBS, 60 min at 22uC, or 0.5% BSA/50% PBS for the
experiment shown in the Figure 4, Panel C) and washed with PBS.
Serial dilutions of proteins were mixed with 125I-FH19-20 or 125I-
OspE (50,000 cpm/well) in a separate 96-well microtitre plate
(Greiner Bio One, Frickenhausen, Germany) before transferring
into the coated wells. After incubation (37uC, 60 min) and
washing with PBS (or 50% PBS for the experiment shown in
Figure 4, Panel C), the radioactivity in each well was measured
with a gamma-counter (Wallac, Turku, Finland). The inhibition
curves were fitted using non-linear regression of a ‘‘log(inhibitor)
vs. response’’ model using GraphPad Prism software (version
5.0b, GraphPad Software, CA, US). The mean inhibitory
concentrations (IC50-values) were calculated from the fitted
curves. All the assays were performed three times using triplicate
wells.
Cofactor assays
To measure cofactor activity 125I-C3b (100,000 cpm/assay) was
mixed with factor I (16 mg/ml) in the absence or presence of FH or
FH1-4 (8–85 mg/ml) and OspE, FhbA, and Tuf (50 mg/ml).
Mixtures were incubated at 37uC for 5 min and, after adding b-
mercaptoethanol, the samples were heated (3 min at 93uC) and
run on 10% SDS-PAGE gels. The gels were subjected to
autoradiography and cofactor activity was evaluated as the
intensity of the C3b a9-chain measured with GelEval-programme
(FrogDance Software, Dundee, UK).
Statistical analyses
Values are expressed as means 6 SD. All statistical analyses
were performed using GraphPad Prism software and statistical
differences were calculated with unpaired t-tests.
Supporting Information
Figure S1 Binding of full length FH to microbes used in
the study. Bacteria and yeast (16108/assay) were incubated with
radiolabeled FH and samples were centrifuged through sucrose
colums to separate unbound radioactivity. Amount of radioactivity
in the pellet and supernatant was measured with a gamma-counter
and FH bound to the microbes is shown as a percentage from total
amount of protein given. Data (%) with SD’s from a representative
experiment performed in triplicates are shown. As negative
controls a serum sensitive strain of H. influenzae and. S. aureus
were used.
(PDF)
Figure S2 Examples of the inhibition assays. Curves from
a single out of three experiments (performed in triplicates) where
inhibition of 125FH19-20 binding to various microbes by wildtype
(wt) and mutant FH19-20 proteins was analyzed to obtain IC50
values (shown in Figure 1). The used microbes were Pseudomonas
aeruginosa (panels A and B), Haemophilus influenzae (panels C and D),
Bordetella pertussis (panels E and F), Streptococcus pneumoniae (panels G
and H), and Candida albicans (panels I and J).
(PDF)
Figure S3 Analyses of general chemical and physical
properties of the key FH19-20 mutant proteins. A,
Circular dichroism spectras of the wildtype and mutant FH19-
20 proteins were similar indicating that all the tested mutant
proteins are most likely folded properly. Crystal structure of the
R1203A mutant has been previously published [41] and found to
be practically the same as the wildtype FH19-20 structure. B,
Purified mutant proteins (35 mM) run through a size exclusion gel
filtration column appeared in the elute within the same fractions as
wildtype FH19-20 implying that the dimerization or oligomeriza-
tion properties of all the tested mutant proteins were similar to the
wildtype.
(PDF)
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Figure S4 Binding of 125I-FH19-20 to microbes is
enhanced in the presence of C3d. Binding of radiolabeled
FH19-20 to indicated microbes was analyzed in the presence (grey
bars) and absence (white bars) of C3d. Data (%) with SD’s from a
representative experiment performed in triplicates are shown.
(PDF)
Figure S5 Correlation between FH19-20 binding to
microbial proteins OspE, FhbA and Tuf and their
enhancing effect on FH-mediated cleavage of the C3b
alpha-chain. Binding of 125I-FH19-20 (data from the Figure 4;
binding of the wild type FH19-20 to proteins without an inhibitor)
is shown as cpm’s (6SD) on the x-axis and the amount of C3b
alpha chain (data from the cofactor-assays presented in the
Figure 6) is shown as percentages (6SD) on the y-axis. OspE binds
more FH19-20 than FhbA and Tuf, and enhances most the
disappearance of C3b alpha-chain.
(PDF)
Table S1 Microbial binding sites on FH. Microbes bind
FH using mainly two interaction sites, one in the domains 6–7 and
another in the C-terminal domains 19–20 (indicated in blue).
Microbial species used in this study are indicated with bold font.
The selected references contain information on binding site(s) of
FH for each microbe.
(PDF)
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